ライフサイエンスコーパス: cardiometabolic

1 Prevalence of 2 or more cardiometabolic abnormalities (high fasting glucose, low

2 al diet during pregnancy might lead to fetal cardiometabolic adaptations with persistent consequences

3 ciated with favorable concentrations of many cardiometabolic and endocrine biomarkers.

4 their relations with intermediate markers of cardiometabolic and endocrine health are less establishe

5 Eating Index (aHEI) diet-quality scores with cardiometabolic and endocrine plasma biomarkers in US wo

6 For most cardiometabolic and general medical outcomes, both group

7 the allelic architecture of risk factors for cardiometabolic and hematological diseases and provide a

8 by association analysis with 20 quantitative cardiometabolic and hematological traits.

9 a range of exposures has been implicated in cardiometabolic and liver disease, but disease predispos

10 fect of this nitric oxide signaling score on cardiometabolic and other diseases.

11 y in women, but the relative contribution of cardiometabolic and other obesity-related comorbidities

12 ith proportionally lower effects mediated by cardiometabolic and other obesity-related conditions, su

13 nce of catch-up growth and largely preserved cardiometabolic and pulmonary functions suggest the pote

14 athway in the development and progression of cardiometabolic and renal disease and is associated with

15 limitations from the perspective of chronic cardiometabolic and renal disease.

16 dult DNA methylation at 5 frequently studied cardiometabolic and stress-response genes (ABCA1, INS-IG

17 ive protein (CRP) is associated with immune, cardiometabolic, and psychiatric traits and diseases.

18 Two novel cardiometabolic associations are at lead variants unique

19 tantial and durable bodyweight reduction and cardiometabolic benefits for young adults.

20 f other dietary factors, are associated with cardiometabolic benefits, particularly improved central

21 tently within </= 12 h every day exerts many cardiometabolic benefits.

22 ious associations between sedentary time and cardiometabolic biomarkers, independent of physical acti

23 viduals with ideal levels for 3-4 of these 4 cardiometabolic biomarkers, those with poor concordance

24 with significant improvements in quality of cardiometabolic care, concordance of treatment with the

25 Most (96%) data requesters of cardiometabolic clinical trial data were from academic c

26 the availability and use of shared data from cardiometabolic clinical trials.

27 ody mass index (BMI) and other components of cardiometabolic (CM) risk during childhood, but evidence

28 an (EA) adults explain racial differences in cardiometabolic (CMB) disease risk.

29 enia or bipolar disorder (0.55 [0.44-0.67]), cardiometabolic comorbidity (dyslipidemia, 0.28 [0.22-0.

30 provide objective risk assessment for future cardiometabolic complications in both normal weight and

31 bution in determining a higher prevalence of cardiometabolic complications in these populations.

32 Although these studies have shown that cardiometabolic complications occur more frequently and

33 al health-related costs associated with high cardiometabolic complications of obesity in Asians has e

34 l to target inflammation to treat or prevent cardiometabolic conditions are still ongoing.

35 In analyses of different combinations of cardiometabolic conditions, odds ratios associated with

36 s may not translate into risk reductions for cardiometabolic conditions.

37 diagnosed eating disorders may have adverse cardiometabolic consequences, including overweight or ob

38 , the underlying pathways, and the long-term cardiometabolic consequences.

39 In 2012, 702308 cardiometabolic deaths occurred in US adults, including

40 etween 2002 and 2012, population-adjusted US cardiometabolic deaths per year decreased by 26.5%.

41 he largest numbers of estimated diet-related cardiometabolic deaths were related to high sodium (6650

42 gh sodium (66508 deaths in 2012; 9.5% of all cardiometabolic deaths), low nuts/seeds (59374; 8.5%), h

43 n studies (GWAS) have identified hundreds of cardiometabolic disease (CMD) risk loci.

44 e more recent rise of obesity and associated cardiometabolic disease (OACD).

45 t etiological component in insulin-resistant cardiometabolic disease and highlight genes and mechanis

46 ns between early growth phenotypes and adult cardiometabolic disease are in part the result of shared

47 (GDM) and gestational hypertension (GH) with cardiometabolic disease has not been well studied.

48 ciations of a combined GDM/GH indicator with cardiometabolic disease in mothers and with diabetes in

49 The relationship between body weight and cardiometabolic disease may vary substantially by race/e

50 estimates of the association between BMI and cardiometabolic disease outcomes and traits, such as pul

51 the effect of the 1p13 rs12740374 variant on cardiometabolic disease phenotypes via transcriptomics a

52 f the field of nutrigenomics with respect to cardiometabolic disease research and outline a direction

53 luate trends of protein source on markers of cardiometabolic disease risk and kidney function in US a

54 measurements and significant improvements in cardiometabolic disease risk characteristics over the 24

55 est differential effects by diet on numerous cardiometabolic disease risk factors.Metabolomic profili

56 when considering the effects on body weight, cardiometabolic disease risk, and bone health.

57 I are emerging markers of future obesity and cardiometabolic disease risk, but little is known about

58 genetic basis of adiposity and its links to cardiometabolic disease risk, we conducted a genome-wide

59 rage capacity) can have different impacts on cardiometabolic disease risk.

60 hms are prospective entry points to mitigate cardiometabolic disease risk.

61 s and developing new therapeutic options for cardiometabolic disease treatment and prevention.

62 ly interconnected with clinical analytes for cardiometabolic disease).

63 Cardiometabolic disease, spanning conditions such as obe

64 istance is a key mediator of obesity-related cardiometabolic disease, yet the mechanisms underlying t

65 opmentally programmed obesity and associated cardiometabolic disease.

66 he multiple organ systems that contribute to cardiometabolic disease.

67 tial of microRNAs (miRNAs) as biomarkers for cardiometabolic disease.

68 may be one link between SSB consumption and cardiometabolic disease.

69 e nucleotide polymorphisms in these genes to cardiometabolic disease.

70 ation of the biology of specific lincRNAs in cardiometabolic disease.

71 ies to explain inter-individual variation in cardiometabolic disease.

72 indings linking methylation to adiposity and cardiometabolic disease.

73 t nutrition and understanding and preventing cardiometabolic disease.

74 neral adiposity (body mass index [BMI]) with cardiometabolic disease.

75 r body mass index (BMI) is a risk factor for cardiometabolic disease; however, the underlying causal

76 re to assess associations with the following cardiometabolic diseases (cases/controls): T2DM (26,488/

77 th gut microbiome data associated with other cardiometabolic diseases (obesity and type 2 diabetes),

78 e increase in height and linking height with cardiometabolic diseases and cancer are insulin and insu

79 Among chronic non-communicable diseases, cardiometabolic diseases and cancer are the most importa

80 related to height, and its association with cardiometabolic diseases and cancer, is becoming even mo

81 c studies has uncovered novel biomarkers for cardiometabolic diseases and clarified the molecular ass

82 elet reactivity, however, is associated with cardiometabolic diseases and enhanced potential for thro

83 of individual dietary factors with specific cardiometabolic diseases are not well established.

84 Cardiometabolic diseases are the leading cause of death

85 We then validated the onset sequences of 5 cardiometabolic diseases by comparing the overall probab

86 that did observe increased risks of these 4 cardiometabolic diseases for an equivalent increase in c

87 ease offspring risk for low birth weight and cardiometabolic diseases in adulthood.

88 , designed to understand the determinants of cardiometabolic diseases in individuals from South Asia.

89 core molecular clock, has been implicated in cardiometabolic diseases in mice and humans.

90 The literature on risk factors for cardiometabolic diseases showed that lutein might be ben

91 and insufficient sleep are risk factors for cardiometabolic diseases, but data on how insufficient s

92 iations between circulating urate levels and cardiometabolic diseases, causality remains uncertain.

93 Chronic sleep disturbances, associated with cardiometabolic diseases, psychiatric disorders and all-

94 have been studied in relation to individual cardiometabolic diseases, their association with risk of

95 se tissue is associated with obesity-related cardiometabolic diseases, whereas lower-body (gluteal an

96 cly available resource for investigations in cardiometabolic diseases.

97 g changes toward potentially higher risk for cardiometabolic diseases.

98 mmunometabolism plays a central role in many cardiometabolic diseases.

99 ribute to the ethnic disparities in risks of cardiometabolic diseases.

100 besity is a highly prevalent risk factor for cardiometabolic diseases.

101 ctices to reduce the burdens of diet-related cardiometabolic diseases.

102 ow extensively these data have been used for cardiometabolic diseases.

103 ion between higher BMI and increased risk of cardiometabolic diseases.

104 syndrome, we studied the ages at onset of 5 cardiometabolic diseases: abdominal obesity, diabetes, h

105 mption of 10 foods/nutrients associated with cardiometabolic diseases: fruits, vegetables, nuts/seeds

106 uals had a higher prevalence of diabetes and cardiometabolic disorders in a community-based populatio

107 between the sexes in their risk of important cardiometabolic disorders such as obesity and cardiovasc

108 Diabetes and multiple cardiometabolic disorders were defined according to stan

109 tissue (VAT) precipitates the development of cardiometabolic disorders.

110 tifying individuals at risk for diabetes and cardiometabolic disorders.

111 s a potential target for type 2 diabetes and cardiometabolic disorders.

112 Our study therefore suggests that cardiometabolic disturbances have an impact on periphera

113 improved glucose tolerance, body weight, and cardiometabolic disturbances in patients with schizophre

114 teract antipsychotic-induced weight gain and cardiometabolic disturbances reported limited effects.

115 Obesity and cardiometabolic dysfunction are associated with increase

116 on the development of obesity and associated cardiometabolic dysfunction in a murine model.

117 for weight loss would avert the unfavorable cardiometabolic effects associated with GCKR Leu446Pro w

118 itness with ILI did not mitigate the adverse cardiometabolic effects of GCKR inhibition in overweight

119 More investigation is needed on the cardiometabolic effects of phenolics, dairy fat, probiot

120 R signaling exerts physiologically important cardiometabolic effects that are distinct from canonical

121 control in diabetes mellitus; however, their cardiometabolic effects, particularly in relation to inc

122 re also associated with at least one related cardiometabolic entity (P < 9.58 x 10(-5)).

123 with significantly higher risk for incident cardiometabolic events and death, independent of blood p

124 adjustment for demographic, behavioral, and cardiometabolic factors, and CRP and interleukin-6, each

125 f obesity class II total effect mediated via cardiometabolic factors: general health 27.0% [men] vers

126 Association of cardiometabolic genes with arsenic metabolism biomarkers

127 leotide polymorphisms (SNPs) from each of 15 cardiometabolic genome-wide association study datasets i

128 Cardiometabolic health and intermediate outcomes, behavi

129 Given that childhood adversities affect cardiometabolic health and multiple health domains acros

130 Adiposity plays a determining role in cardiometabolic health at a young age.

131 t lutein is suggested as being beneficial to cardiometabolic health because of its protective effect

132 In this statement, we review the cardiometabolic health effects of specific eating patter

133 ms achieved clinically meaningful weight and cardiometabolic health improvements.

134 d to disordered eating behaviors, and future cardiometabolic health is, to our knowledge, unknown.

135 ch eating styles can have various effects on cardiometabolic health markers, namely obesity, lipid pr

136 Little is known about the cardiometabolic health of internal migrant workers in Ch

137 ciated with insulin resistance and increased cardiometabolic health risk compared to birth at full te

138 ons variably improve MVPA levels and related cardiometabolic health sequelae of working-age women in

139 s targeting MVPA levels and known beneficial cardiometabolic health sequelae were of lower quality ev

140 s and coarsened exact matching to assess how cardiometabolic health varies among those entering, exit

141 We aimed to determine the impact of soy on cardiometabolic health, adipose tissue inflammation, and

142 we found significant improvements in weight, cardiometabolic health, and weight-related quality of li

143 etween the equol producer (EP) phenotype and cardiometabolic health, few studies have prospectively r

144 ually outlines pathways linking adversity to cardiometabolic health, identifies evidence gaps, and pr

145 ntake of added sugars has adverse effects on cardiometabolic health, which is consistent with many re

146 ell as current residential circumstances for cardiometabolic health.

147 lutein are generally associated with better cardiometabolic health.

148 g parental socioeconomic position, and adult cardiometabolic health.

149 an systems for early intervention to improve cardiometabolic health.

150 ute to the beneficial effects of exercise on cardiometabolic health.

151 rograms, improving MVPA levels and enhancing cardiometabolic health.

152 l effects of this metabolite on exercise and cardiometabolic health.

153 nd gained less weight; other vital signs and cardiometabolic laboratory findings did not differ betwe

154 M19A2 associations were independent of known cardiometabolic loci.

155 onsiveness and are differentially related to cardiometabolic markers.

156 heart disease, stroke, and type 2 diabetes (cardiometabolic mortality) among US adults.

157 n important risk factor for both hepatic and cardiometabolic mortality.

158 e we aimed to establish the risk of incident cardiometabolic multimorbidity (ie, at least two from: t

159 The main outcome was cardiometabolic multimorbidity (ie, developing at least

160 vidual-participant data for BMI and incident cardiometabolic multimorbidity from 16 prospective cohor

161 ith a healthy weight, the risk of developing cardiometabolic multimorbidity in overweight individuals

162 INTERPRETATION: The risk of cardiometabolic multimorbidity increases as BMI increase

163 lic diseases, their association with risk of cardiometabolic multimorbidity is poorly understood.

164 Incident cardiometabolic multimorbidity was ascertained via resur

165 association between childhood adversity and cardiometabolic outcomes across the life course.

166 ion were used to assess associations between cardiometabolic outcomes and water As or the sum of inor

167 Primary analyses assessed the difference in cardiometabolic outcomes between EPA and DHA.

168 nal adrenal tumors (NFATs) increase risk for cardiometabolic outcomes compared with absence of adrena

169 ects of lutein (intake or concentrations) on cardiometabolic outcomes in different life stages.

170 iseases, yet reports on its association with cardiometabolic outcomes in the literature are conflicti

171 structures, are known to be associated with cardiometabolic outcomes over the life course into adult

172 e on the influence of childhood adversity on cardiometabolic outcomes that constitute the greatest pu

173 trations, dietary intake, or supplements and cardiometabolic outcomes was reported.

174 Medications showed small or no benefit for cardiometabolic outcomes, including fasting glucose leve

175 ations from the median BMI for age and sex), cardiometabolic outcomes, quality of life, other health

176 low-calorie sweeteners and fruit juices with cardiometabolic outcomes, since decisions about whether

177 e reproductive, educational, psychiatric and cardiometabolic outcomes.

178 riability, are heritable, and associate with cardiometabolic outcomes.

179 in advanced glycation end products (AGEs) on cardiometabolic parameters are conflicting.

180 parallel with improvements in post-procedure cardiometabolic parameters.

181 nd points included change in body weight and cardiometabolic parameters.

182 ndrome (MetS), defined by a constellation of cardiometabolic pathologies, is highly prevalent among v

183 provide evidence that PTSD confers risk for cardiometabolic pathology and neurodegeneration and rais

184 hether methylation was associated with adult cardiometabolic phenotype.

185 e association of central obesity and related cardiometabolic phenotypes above and beyond body mass in

186 lth strategies aimed at improving children's cardiometabolic profile should strive for increasing phy

187 ppear less favorable for achieving a healthy cardiometabolic profile.

188 s may be an effective strategy for improving cardiometabolic profiles in individuals with and without

189 to play important roles in breast cancer and cardiometabolic regulation, but many questions remain ab

190 Little evidence to date supports the cardiometabolic relevance of other popular priorities: e

191 lative to mouse, expression patterns in five cardiometabolic-relevant tissues, and allele-specific ex

192 of MVD in the development and progression of cardiometabolic/renal disease.

193 associated with several markers of increased cardiometabolic risk (diabetes, triglyceridemia, and cho

194 lating sleep duration and sleep disorders to cardiometabolic risk and call for health organizations t

195 ole of methylation in socioeconomic position-cardiometabolic risk associations.

196 A higher score indicates a higher cardiometabolic risk at age 4.

197 cal activity (P = 0.028) predicted clustered cardiometabolic risk at follow-up, but these association

198 d sex-specific thresholds of MS, for optimal cardiometabolic risk categorization among Colombian chil

199 measurements and significant improvements in cardiometabolic risk characteristics were observed over

200 measurements and significant improvements in cardiometabolic risk characteristics were observed over

201 nd visceral fat deposition, and an increased cardiometabolic risk compared with subcutaneous fat.

202 and adolescents; and to investigate whether cardiometabolic risk differed by MS group by applying th

203 egated pre- and post-intervention weight and cardiometabolic risk factor changes (fasting blood gluco

204 No prior analyses have aggregated weight and cardiometabolic risk factor changes observed in studies

205 asions could lead to healthier lifestyle and cardiometabolic risk factor management.

206 during childhood (up to 18 years of age) and cardiometabolic risk factors (body mass index, fat mass

207 mediated by related comorbidities, including cardiometabolic risk factors (diabetes mellitus, hyperte

208 lely to increased body weight and associated cardiometabolic risk factors (e.g.,dyslipidemia or hyper

209 re few therapeutic recommendations for these cardiometabolic risk factors and little evidence of thei

210 However, we observed different changes in cardiometabolic risk factors and nutritional markers bet

211 We examined cardiometabolic risk factors and pathways associated wit

212 abolites have differential associations with cardiometabolic risk factors and subtypes of vascular di

213 Studies showed improvements in cardiometabolic risk factors and, in several, androgen e

214 d-effects models to estimate mean changes in cardiometabolic risk factors associated with changes in

215 Sociodemographic, behavioural, and cardiometabolic risk factors from 1985 and chronic condi

216 sical activity with individual and clustered cardiometabolic risk factors in healthy children aged 10

217 o examine the prevalence of diabetes-related cardiometabolic risk factors in this large, but little-s

218 lunch with that at dinner on weight loss and cardiometabolic risk factors in women during a weight-lo

219 ith LF yogurt consumption on body weight and cardiometabolic risk factors in women during a weight-lo

220 ubcomponent of physical activity may predict cardiometabolic risk factors in youths.We examined the i

221 LSG can significantly improve cardiometabolic risk factors including glycemic status i

222 Continuous AsIII exposure increased cardiometabolic risk factors including increased body we

223 e observed polygenic overlap between CAD and cardiometabolic risk factors indicates a pathogenic rela

224 that sensitize the genome to these and other cardiometabolic risk factors of the diabetic milieu are

225 as not associated with any of the individual cardiometabolic risk factors or clustered cardiometaboli

226 ood foreclosures had mixed associations with cardiometabolic risk factors over time.

227 HS exposure is associated with clustering of cardiometabolic risk factors such as obesity, dyslipidem

228 verse relation between physical activity and cardiometabolic risk factors that is independent of sede

229 tions of parental separation with children's cardiometabolic risk factors were largely null.

230 d with the general population in China, most cardiometabolic risk factors were less prevalent in migr

231 ith a serious mental illness and one or more cardiometabolic risk factors were randomly assigned to e

232 anges in body weight, coexisting conditions, cardiometabolic risk factors, and weight-related quality

233 a choline and choline-related compounds with cardiometabolic risk factors, history of cardiovascular

234 to examine relations of plasma measures with cardiometabolic risk factors, history of cardiovascular

235 se migrant workers had none of the following cardiometabolic risk factors, including current cigarett

236 Secondary outcomes were cardiometabolic risk factors, nutritional outcomes, adve

237 had a high prevalence of cardiovascular and cardiometabolic risk factors, similar to patients with t

238 10-y interval that included measurements of cardiometabolic risk factors, were included in the study

239 ignificant effects on several other nonlipid cardiometabolic risk factors.

240 p bridge the equity gap in the management of cardiometabolic risk factors.

241 ffects of n-3 (omega-3) fatty acids (FAs) on cardiometabolic risk factors.

242 impairment and is not confounded by various cardiometabolic risk factors.

243 asured by whole-body MRI after adjusting for cardiometabolic risk factors.

244 mine the effect of low AGE diets in reducing cardiometabolic risk factors.

245 al amounts of SFAs from cheese and butter on cardiometabolic risk factors.In a multicenter, crossover

246 h temporal changes in 3 objectively measured cardiometabolic risk factors: body mass index, systolic

247 natal PFAS exposures and outcomes related to cardiometabolic risk in a cohort of Spanish children fol

248 ing evidence suggests that psoriasis poses a cardiometabolic risk in children, as in adults.

249 ntary time, is prospectively associated with cardiometabolic risk in healthy children.

250 al cardiometabolic risk factors or clustered cardiometabolic risk in prospective analyses.

251 ther this recommendation effectively reduces cardiometabolic risk is not well understood.

252 provide evidence that their link with higher cardiometabolic risk is underpinned by an association wi

253 mentation on blood pressure and conventional cardiometabolic risk markers are inconsistent.

254 othelial function, and the more conventional cardiometabolic risk markers.

255 Synergistic or additive effects or both on cardiometabolic risk may be missed by examining individu

256 a BMI criterion for overweight to screen for cardiometabolic risk may result in a large proportion of

257 ations of multiple fatty acids may influence cardiometabolic risk more than single fatty acids.

258 in utero influences may contribute to higher cardiometabolic risk observed in Indian and Malay person

259 in could be a major factor in increasing the cardiometabolic risk of Asian populations at a lower BMI

260 pediatric psoriasis have a more atherogenic cardiometabolic risk profile, with evidence of insulin r

261 ncentrations are associated with an advanced cardiometabolic risk profile.

262 or was well tolerated and improved patients' cardiometabolic risk profile.

263 Cardiometabolic risk profiles for migrant workers are no

264 ose tissue (VAT) are associated with adverse cardiometabolic risk profiles.

265 and analyzed individually and as a clustered cardiometabolic risk score standardized by age and sex (

266 een arsenic exposure and multiple markers of cardiometabolic risk using drinking-water As measurement

267 ween genetic variants and diet in modulating cardiometabolic risk, as well as the effects of dietary

268 uggests that height is associated with lower cardiometabolic risk, but higher cancer risk, associatio

269 atal PFAS exposures and outcomes relevant to cardiometabolic risk, including a composite CM-risk scor

270 ers have emerged as being related to adverse cardiometabolic risk, including obesity, hypertension, t

271 Moderate exposure to As may increase cardiometabolic risk, particularly in individuals with h

272 ted with characteristics of both a favorable cardiometabolic risk-factor profile (higher HDL choleste

273 choline were associated with an unfavorable cardiometabolic risk-factor profile [lower high-density

274 sma betaine were associated with a favorable cardiometabolic risk-factor profile [lower low-density l

275 he negative covariance between BW and future cardiometabolic risk.

276 hese levels of exposure, are associated with cardiometabolic risk.

277 and blood pressure were used to characterize cardiometabolic risk.

278 es for hypertension, emphasizing a link with cardiometabolic risk.

279 ntial impact of gastrointestinal function on cardiometabolic risk.

280 ted with systemic inflammation and increased cardiometabolic risk.

281 Chronic exposure to arsenic and markers of cardiometabolic risk: a cross-sectional study in Chihuah

282 ry fat per se promotes ectopic adiposity and cardiometabolic syndrome in humans.

283 linical trials, of which 537 (16%) evaluated cardiometabolic therapeutics (phase 1, 36%; phase 2, 17%

284 Thirty of these proposals were related to cardiometabolic therapies and requested data from 79 uni

285 examined variants previously associated with cardiometabolic traits ( 200,000 from Illumina Cardio M

286 ng, we searched causal variants across eight cardiometabolic traits (BMI, systolic and diastolic bloo

287 examined variants previously associated with cardiometabolic traits (~ 200,000 from Illumina Cardio M

288 the relation between L-ascorbic acid and 10 cardiometabolic traits by using a single nucleotide poly

289 otype association signatures with a range of cardiometabolic traits revealing new insights in the lin

290 Estimates for cardiometabolic traits were based on a combined data set

291 We sought to examine the association of cardiometabolic traits with left ventricular (LV) cardia

292 The association of this score with cardiometabolic traits, type 2 diabetes, and CHD was tes

293 s, we examined the impact of this variant on cardiometabolic traits, type 2 diabetes, and coronary he

294 nts implicate biological pathways related to cardiometabolic traits, vascular function, and developme

295 Illustrating with cardiometabolic traits, we show that while genomic resea

296 from dietary intake and the microbiota with cardiometabolic traits.

297 oke subtypes; secondary analyses included 18 cardiometabolic traits.

298 ted loci are enriched for known variants for cardiometabolic traits.

299 sociations, and polygenic risk estimates for cardiometabolic traits.

300 Despite availability of data from >500 cardiometabolic trials in a multisponsor data-sharing pl